Please use this identifier to cite or link to this item:
Title: Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma
Authors: Hui, EP
Chan, KCA
Chan, CML
Wong, CSC 
To, KF
Chan, AWH
Tung, SY
Ng, WT
Cheng, AC
Lee, VHF
Chan, SL
Loong, HHF
Kam, MKM
Leung, SF
Ho, R
Mo, F
Ngan, RKC
Chan, ATC
Keywords: Biomarker
Epstein-Barr virus DNA
Nasopharyngeal cancer
Single nucleotide polymorphism
Issue Date: 2015
Publisher: John Wiley & Sons
Source: Cancer, 2015, v. 121, no. 16, p. 2720-2729 How to cite?
Journal: Cancer 
Abstract: BACKGROUND Single nucleotide polymorphism (SNP) of the excision repair cross-complementing group 1 (ERCC1) gene has been linked with sensitivity to platinum and radiation. The authors hypothesized that the ERCC1 genotype for the SNPs cytosine-to-thymine substitution at codon 118 (C118T) and cytosine-to-adenine substitution at codon 8092 (C8092A) is prognostic in patients with nasopharyngeal carcinoma (NPC) who receive either radiotherapy (RT) or cisplatin plus RT. METHODS The authors tested their hypothesis using biomarker screening samples from the Hong Kong NPC Study Group 0502 trial, which was a prospective, multicenter clinical trial that used post-RT plasma Epstein-Bar virus (EBV) DNA (pEBV) levels to screen patients with high-risk NPC for adjuvant chemotherapy. RESULTS ERCC1 SNPs were analyzed in 576 consecutive patients who were screened by pEBV. In the total biomarker population, there was no significant association of ERCC1 C118T or C8092A genotype with relapse-free survival (RFS) or overall survival (OS). There also was no correlation between ERCC1 genotype and ERCC1 protein or messenger RNA expression in a subset of patients who had available paired biopsies. Post-RT pEBV status was the only independent prognosticator for RFS and OS in multivariate analyses. However, there was a significant interaction between ERCC1 C118T genotype and post-RT pEBV status (RFS, P=.0106; OS, P=.0067). The ERCC1 C118T genotype was significantly associated with both RFS (hazard ratio, 1.67; 95% confidence interval, 1.07-2.61; P=.024) and OS (hazard ratio, 2.31; 95% confidence interval, 1.22-4.40; P=.0106) in the post-RT pEBV-negative population, but not in the pEBV-positive population. CONCLUSIONS The current results prospectively validate pEBV as the most significant prognostic biomarker in NPC that can be used to select high-risk patients for adjuvant therapy. The ERCC1 C118T genotype may help to identify a favorable subgroup (approximately 7%) of pEBV-negative patients with NPC who have an excellent prognosis and can be spared the toxicities of further therapy. Cancer 2015;121:2720-2729.American Cancer Society The results of this study demonstrate the psychometric validity of the Penn Arthralgia Aging Scale among breast cancer survivors on aromatase inhibitors. This scale captures women's perceptions of aging due to arthralgia and predicts incremental variance in depression, anxiety, and pain interference above and beyond joint pain severity ? 2015 American Cancer Society.
ISSN: 0008-543X
EISSN: 1097-0142
DOI: 10.1002/cncr.29413
Appears in Collections:Journal/Magazine Article

View full-text via PolyU eLinks SFX Query
Show full item record


Last Week
Last month
Citations as of Nov 8, 2018


Last Week
Last month
Citations as of Nov 17, 2018

Page view(s)

Last Week
Last month
Citations as of Nov 12, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.